{"title":"Teprotumumab和Tocilizumab在中重度类固醇抵抗性甲状腺眼病中的实际应用","authors":"Anupam Kotwal","doi":"10.1089/ct.2023;35.364-367","DOIUrl":null,"url":null,"abstract":"Clinical Thyroidology®Vol. 35, No. 9 Thyroid Eye DiseaseReal-World Use of Teprotumumab and Tocilizumab in Moderate-to-Severe Steroid-Resistant Thyroid Eye DiseaseAnupam KotwalAnupam KotwalDivision of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.Search for more papers by this authorPublished Online:13 Sep 2023https://doi.org/10.1089/ct.2023;35.364-367AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 35Issue 9Sep 2023 Information© Copyright 2023, Mary Ann Liebert, Inc.To cite this article:Anupam Kotwal.Real-World Use of Teprotumumab and Tocilizumab in Moderate-to-Severe Steroid-Resistant Thyroid Eye Disease.Clinical Thyroidology®.Sep 2023.364-367.http://doi.org/10.1089/ct.2023;35.364-367Published in Volume: 35 Issue 9: September 13, 2023PDF download","PeriodicalId":72629,"journal":{"name":"Clinical thyroidology","volume":"30 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-World Use of Teprotumumab and Tocilizumab in Moderate-to-Severe Steroid-Resistant Thyroid Eye Disease\",\"authors\":\"Anupam Kotwal\",\"doi\":\"10.1089/ct.2023;35.364-367\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Clinical Thyroidology®Vol. 35, No. 9 Thyroid Eye DiseaseReal-World Use of Teprotumumab and Tocilizumab in Moderate-to-Severe Steroid-Resistant Thyroid Eye DiseaseAnupam KotwalAnupam KotwalDivision of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.Search for more papers by this authorPublished Online:13 Sep 2023https://doi.org/10.1089/ct.2023;35.364-367AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 35Issue 9Sep 2023 Information© Copyright 2023, Mary Ann Liebert, Inc.To cite this article:Anupam Kotwal.Real-World Use of Teprotumumab and Tocilizumab in Moderate-to-Severe Steroid-Resistant Thyroid Eye Disease.Clinical Thyroidology®.Sep 2023.364-367.http://doi.org/10.1089/ct.2023;35.364-367Published in Volume: 35 Issue 9: September 13, 2023PDF download\",\"PeriodicalId\":72629,\"journal\":{\"name\":\"Clinical thyroidology\",\"volume\":\"30 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical thyroidology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1089/ct.2023;35.364-367\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical thyroidology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/ct.2023;35.364-367","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Real-World Use of Teprotumumab and Tocilizumab in Moderate-to-Severe Steroid-Resistant Thyroid Eye Disease
Clinical Thyroidology®Vol. 35, No. 9 Thyroid Eye DiseaseReal-World Use of Teprotumumab and Tocilizumab in Moderate-to-Severe Steroid-Resistant Thyroid Eye DiseaseAnupam KotwalAnupam KotwalDivision of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.Search for more papers by this authorPublished Online:13 Sep 2023https://doi.org/10.1089/ct.2023;35.364-367AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 35Issue 9Sep 2023 Information© Copyright 2023, Mary Ann Liebert, Inc.To cite this article:Anupam Kotwal.Real-World Use of Teprotumumab and Tocilizumab in Moderate-to-Severe Steroid-Resistant Thyroid Eye Disease.Clinical Thyroidology®.Sep 2023.364-367.http://doi.org/10.1089/ct.2023;35.364-367Published in Volume: 35 Issue 9: September 13, 2023PDF download
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
